|Ms. Susan B. Washer||Pres, CEO & Director||795.26k||N/A||1961|
|Mr. Stephen W. Potter||VP & Chief Bus. Officer||486.77k||N/A||1956|
|Dr. Matthew Feinsod||Exec. VP of Global Strategy & Devel.||549.67k||N/A||1971|
|Dr. Nicholas Muzyczka||Co-Founder||N/A||N/A||N/A|
|Dr. Barry J. Byrne||Co-Founder||N/A||N/A||N/A|
|Dr. William W. Hauswirth||Co-Founder & Member of Ophthalmology Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Richard Jude Samulski||Co-Founder||N/A||N/A||N/A|
|Dr. Terence R. Flotte M.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Gerald Anthony Reynolds||Chief Accounting Officer, Principal Accounting Officer & Treasurer||N/A||N/A||N/A|
|Ms. Janet C. Rae RAC||Sr. VP of Global Regulatory & Quality||N/A||N/A||N/A|
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Applied Genetic Technologies Corporation’s ISS Governance QualityScore as of July 1, 2021 is 6. The pillar scores are Audit: 9; Board: 1; Shareholder Rights: 7; Compensation: 9.